BioCardia registers $57.5 million of stock for initial public offering

Cantor Fitzgerald, Roth Capital Partners, Maxim Group assist with sale

By Devika Patel

Knoxville, Tenn., June 16– BioCardia, Inc. will price its initial public sale of common stock with a 30-day greenshoe, according to a Form S-1 filed Tuesday with the Securities and Exchange Commission. The company has registered up to $57.5 million of stock.

Cantor Fitzgerald & Co. is the bookrunner. Roth Capital Partners is the lead manager and Maxim Group LLC is the co-manager.

Proceeds will be used for clinical trials, working capital, research and development of additional future products or therapies and general corporate purposes.

The clinical-stage regenerative medicine company is based in San Carlos, Calif. The company intends to list its common stock on the Nasdaq stock exchange under the symbol “BCDA.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.